Personas / Equipo Humano

Sara Pérez Jaume

Buscador de publicaciones

Publicaciones

  • Esther Martínez García, López de San Roman Fernández C, Nishishinya Aquino MB, Pérez-Jaume S, Fernández-Jané C, Cruz-Martínez O and Morales-La Madrid A.

    Patient Acceptability of the First Integrative Pediatric Oncology Unit in Spain-The Pediatric Cancer Center Barcelona Experience: A Retrospective Study

    Cancers . 17(2): .

    [doi:10.3390/cancers17020222]

  • Pérez-Jaume S and Carrasco, Josep L..

    Comparison of optimum threshold estimators in the binormal setting

    JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION . : .

    [doi:10.1080/00949655.2024.2444495]

  • Cristina Larrosa Espinosa, Mico S, Ramos M, Pérez-Jaume S, Sánchez M, Castañeda-Heredia A, Garraus-Oneca M and Mora J.

    Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomes

    PEDIATRIC BLOOD & CANCER . 71(10): .

    [doi:10.1002/pbc.31221]

  • Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK.

    Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects

    Frontiers in oncology . 14: 1380917-1380917.

    [doi:10.3389/fonc.2024.1380917]

  • Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.

    Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy

    Cancers . 16(9): . Nº de citas: 1

    [doi:10.3390/cancers16091735]

  • Fresno Cañada C, Gispets Parcerisas J, Del Prado-Sanchez C, Puigventós E, Pérez-Jaume S, Salvador-Hernandez H, Llorca Cardeñosa A and Prat-Bartomeu J.

    DRI Triton SS-OCT applied to detect choroidal nodules in paediatric patients affected by NF1

    Heliyon . 10(8): . Nº de citas: 1

    [doi:10.1016/j.heliyon.2024.e29263]

  • Aschero MR, Ganiewich D, Lamas G, Restrepo-Perdomo CA, Ottaviani D, Zugbi S, Camarero S, Néspoli E, Cuadrado-Vilanova M, Pérez-Jaume S, Pascual-Pastó G, Sampor C, Grigorovski N, Salas B, Suñol M, Carcaboso AM, Mora J, de Dávila MTG, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lubieniecki F and Chantada G.

    Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma

    PEDIATRIC BLOOD & CANCER . 71(1): . Nº de citas: 3

    [doi:10.1002/pbc.30717]

  • Simao-Rafael M, Cruz-Martínez O, Pérez-Jaume S, Santa-María López V, Lavarino C, Salvador-Hernandez H, Muchart-Lopez J, Hinojosa J, Suñol M and Morales-La Madrid A.

    Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center

    EJC Paediatric Oncology . 2: 100115.

    [doi:10.1016/j.ejcped.2023.100115]

  • Ana Carolina Izurieta Pacheco, Sangrós-Gimenez A, Martínez-Garcia E, Pérez-Jaume S, Mora J and Gorostegui-Obanos M.

    Vitamin D Status in Children With High-risk Neuroblastoma

    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY . 45(8): 953-958. Nº de citas: 3

    [doi:10.1097/MPH.0000000000002762]

  • Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J.

    Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes

    Cancers . 15(19): . Nº de citas: 9

    [doi:10.3390/cancers15194837]